Humacyte, Inc. (HUMA), a clinical-stage biotechnology company focused on universally implantable, bioengineered human tissue at commercial scale, announced Tuesday positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel or HAV in vascular trauma repair.
from RTT - Before the Bell https://ift.tt/TFkPUMp
via IFTTT
No comments:
Post a Comment